1 Heart Failure Unit Department of Cardiology Hospital Universitari Germans Trias i Pujol Badalona Spain.
2 Department of Medicine Universitat Autònoma de Barcelona Spain.
J Am Heart Assoc. 2019 Feb 19;8(4):e010887. doi: 10.1161/JAHA.118.010887.
Background Mechanisms underlying iron homeostasis dysregulation in patients with chronic heart failure remain unsettled. In cardiomyocyte models, norepinephrine may lead to intracellular iron depletion, but the potential association between catecholamines (sympathetic activation markers) and iron metabolism biomarkers in chronic heart failure is unknown. Methods and Results In this cross-sectional analysis, we studied the association between plasma norepinephrine levels and serum iron status biomarkers indicating iron storage (ferritin), iron transport (transferrin saturation), and iron demand (soluble transferrin receptor) in a prospective cohort of 742 chronic heart failure patients (mean age, 72±11 years; 56% male). Impaired iron status was defined as ferritin <100 μg/L or transferrin saturation <20%. Impaired iron status was observed in 69% of patients. In multivariate models, greater norepinephrine levels were associated with impaired iron transport (transferrin saturation <20%, odds ratio=2.28; 95% CI [1.19-4.35]; P=0.013), but not with impaired iron storage (ferritin <100 μg/L, odds ratio=1.25; 95% CI [0.73-2.16]; P=0.415). Norepinephrine was a significant predictor of increased iron demand (soluble transferrin receptor, standardized β-coefficient=0.12; P=0.006) and low transferrin saturation (standardized β-coefficient=-0.12; P=0.003). However, norepinephrine levels were not associated with iron or ferritin levels ( P>0.05). Adjusted norepinephrine marginal means were significantly higher in patients with impaired iron status compared with those with normal iron status (528 pg/mL [505-551] versus 482 pg/mL [448-518], respectively; P=0.038). Conclusions In chronic heart failure patients, increased sympathetic activation estimated with norepinephrine levels is associated with impaired iron status and, particularly, dysregulation of biomarkers suggesting impaired iron transport and increased iron demand. Whether the relationship between norepinephrine and iron metabolism is bidirectional and entails causality need to be elucidated in future research.
慢性心力衰竭患者铁稳态失调的机制仍未确定。在心肌细胞模型中,去甲肾上腺素可能导致细胞内铁耗竭,但儿茶酚胺(交感神经激活标志物)与慢性心力衰竭中铁代谢生物标志物之间的潜在关联尚不清楚。
在这项横断面分析中,我们研究了在一个前瞻性队列的 742 例慢性心力衰竭患者(平均年龄 72±11 岁;56%为男性)中,血浆去甲肾上腺素水平与血清铁状态生物标志物(反映铁储存的铁蛋白、铁转运的转铁蛋白饱和度和铁需求的可溶性转铁蛋白受体)之间的关系。铁状态受损定义为铁蛋白<100μg/L 或转铁蛋白饱和度<20%。69%的患者存在铁状态受损。在多变量模型中,较高的去甲肾上腺素水平与铁转运受损(转铁蛋白饱和度<20%,比值比=2.28;95%CI[1.19-4.35];P=0.013)相关,但与铁储存受损(铁蛋白<100μg/L,比值比=1.25;95%CI[0.73-2.16];P=0.415)无关。去甲肾上腺素是铁需求增加(可溶性转铁蛋白受体,标准化β系数=0.12;P=0.006)和低转铁蛋白饱和度(标准化β系数=-0.12;P=0.003)的显著预测因子。然而,去甲肾上腺素水平与铁或铁蛋白水平无关(P>0.05)。与铁状态正常的患者相比,铁状态受损的患者调整后的去甲肾上腺素边缘均值显著更高(分别为 528pg/mL[505-551]和 482pg/mL[448-518];P=0.038)。
在慢性心力衰竭患者中,用去甲肾上腺素估计的交感神经激活增加与铁状态受损相关,特别是与铁转运标志物异常和铁需求增加有关。去甲肾上腺素与铁代谢之间的关系是否是双向的,是否存在因果关系,需要在未来的研究中阐明。